A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response.

High doses of GH, used to induce anabolism in prolonged critically ill patients, unexpectedly increased mortality. To further explore underlying mechanisms, a valid animal model is needed. Such a model is presented in this study. Seven days after arterial and venous cannulae placement, male New Zealand White rabbits were randomly allocated to a control or a critically ill group. To induce prolonged critical illness, a template controlled 15% deep dermal burn injury was imposed under combined general and regional (paravertebral) anesthesia. Subsequently, critically ill rabbits received supplemental analgesia and were parenterally fed with glucose, insulin, amino acids, and lipids. On d 1 and d 8 after randomization, acute and chronic spontaneous hormonal profiles of GH, TSH, and PRL secretion were obtained by sampling blood every 15 min for 7 h. Furthermore, GH, TSH, and PRL responses to an iv bolus of GH-releasing peptide 2 (GHRP-2) + TRH were documented on d 0, 1, and 8. Hemodynamic status and biochemical parameters were evaluated on d 0, 1, 3, 5, and 8, after which animals were killed and relative wet weight and water content of organs was determined. Compared with controls, critically ill animals exhibited transient metabolic acidosis on d 1 and weight loss, organ wasting, systolic hypertension, and pronounced anemia on d 8. On d 1, pulsatile GH secretion doubled in the critically ill animals compared with controls, and decreased again on d 8 in the presence of low plasma IGF-I concentrations from d 1 to d 8. GH responses to GHRP-2 + TRH were elevated on d 1 and increased further on d 8 in the critically ill animals. Mean TSH concentrations were identical in both groups on d 1 and 8, in the face of dramatically suppressed plasma T(4) and T(3) concentrations in the critically ill animals. PRL secretion was impaired in the critically ill animals exclusively on d 8. TSH and PRL responses to GHRP-2 and TRH were increased only on d 1. In conclusion, this rabbit model of acute and prolonged critical illness reveals several of the clinical, biochemical, and endocrine manifestations of the human counterpart.

[1]  V. Lenaerts,et al.  Growth hormone-releasing activity of hexarelin in humans , 1994, European Journal of Clinical Pharmacology.

[2]  S. Anderson,et al.  Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. , 2001, The Journal of clinical endocrinology and metabolism.

[3]  C. Bowers Unnatural growth hormone-releasing peptide begets natural ghrelin. , 2001, The Journal of clinical endocrinology and metabolism.

[4]  Steven M. Pincus,et al.  Secretory process regularity monitors neuroendocrine feedback and feedforward signaling strength in humans. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  G. Van den Berghe,et al.  A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. , 2000, The Journal of clinical endocrinology and metabolism.

[6]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[7]  N R Webster,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.

[8]  G. Van den Berghe,et al.  Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.

[9]  A. Rahim,et al.  Selective lack of growth hormone (GH) response to the GH-releasing peptide hexarelin in patients with GH-releasing hormone receptor deficiency. , 1999, The Journal of clinical endocrinology and metabolism.

[10]  L. J. Groot,et al.  Dangerous Dogmas in Medicine: The Nonthyroidal Illness Syndrome , 1999 .

[11]  G. Van den Berghe,et al.  Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness. , 1999, European journal of endocrinology.

[12]  I. Robinson,et al.  Effects of growth hormone secretagogues on prolactin release in anesthetized dwarf (dw/dw) rats. , 1998, Endocrinology.

[13]  G. Van den Berghe,et al.  Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. , 1998, The Journal of clinical endocrinology and metabolism.

[14]  A. Barkan,et al.  Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation. , 1998, The Journal of clinical endocrinology and metabolism.

[15]  C. Ryan,et al.  A rabbit model for metabolic studies after burn injury. , 1998, The Journal of surgical research.

[16]  G. Van den Berghe,et al.  Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. , 1998, The Journal of clinical endocrinology and metabolism.

[17]  E. Fliers,et al.  Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness. , 1997, The Journal of clinical endocrinology and metabolism.

[18]  J. Lorente,et al.  Pituitary-thyroid function in patients with septic shock and its relation with outcome. , 1997, European journal of medical research.

[19]  G. Van den Berghe,et al.  The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. , 1997, The Journal of clinical endocrinology and metabolism.

[20]  M. Falchi,et al.  Effect of acute and chronic inflammation on plasma growth hormone levels in rats. , 1997, Drugs under experimental and clinical research.

[21]  G. Van den Berghe,et al.  Pituitary responsiveness to GH‐releasing hormone, GH‐releasing peptide‐2 and thyrotrophin‐releasing hormone in critical illness , 1996, Clinical endocrinology.

[22]  R. Mcdowell,et al.  In vitro characterization of four novel classes of growth hormone-releasing peptide. , 1995, Endocrinology.

[23]  C. Lang,et al.  Alterations in the insulin-like growth factor system in trauma patients. , 1995, The American journal of physiology.

[24]  B. D. Clark,et al.  Suppression of thyrotropin-releasing hormone gene expression by interleukin-1-beta in the rat: implications for nonthyroidal illness. , 1994, Neuroendocrinology.

[25]  C. Sweep,et al.  Different effects of continuous infusion of interleukin-1 and interleukin-6 on the hypothalamic-hypophysial-thyroid axis. , 1994, Endocrinology.

[26]  A. Barkan,et al.  Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. , 1993, The Journal of clinical endocrinology and metabolism.

[27]  B. Atac,et al.  Hematologic changes in massive burn injury , 1992, Critical care medicine.

[28]  J. Verhaeghe,et al.  The effects of systemic insulin, insulin-like growth factor-I and growth hormone on bone growth and turnover in spontaneously diabetic BB rats. , 1992, The Journal of endocrinology.

[29]  J. Miell,et al.  Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin–like growth factor‐I , 1991, Clinical endocrinology.

[30]  S M Pincus,et al.  Approximate entropy as a measure of system complexity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Vance,et al.  Temporal structure of in vivo growth hormone secretory events in humans. , 1991, The American journal of physiology.

[32]  M L Johnson,et al.  The pituitary gland secretes in bursts: appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Beddoe,et al.  Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. , 1987, The Journal of trauma.

[34]  J. Billett,et al.  Fluid retention and burn survival. , 1987, The Journal of trauma.

[35]  S. Wallner,et al.  The Anemia of Thermal Injury: Mechanism of Inhibition of Erythropoiesis 1 , 1986, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[36]  W. Vale,et al.  Involvement of corticotropin-releasing factor and somatostatin in stress-induced inhibition of growth hormone secretion in the rat. , 1985, Endocrinology.

[37]  K. Swedberg,et al.  Endogenous catecholamine levels in chronic heart failure. Relation to the severity of hemodynamic abnormalities. , 1985, The American journal of medicine.

[38]  R. Phillips,et al.  Circulating thyroid hormone changes in acute trauma: prognostic implications for clinical outcome. , 1984, The Journal of trauma.

[39]  J. Kinney,et al.  Effect of an anabolic steroid on nitrogen balance and amino acid patterns after total hip replacement. , 1982, The Journal of trauma.

[40]  R. Utiger Decreased extrathyroidal triiodothyronine production in nonthyroidal illness: benefit or harm? , 1980, The American journal of medicine.

[41]  R. Hoffenberg,et al.  Effects of surgical stress and corticotrophin on the peripheral metabolism of thyroid hormones in rabbits. , 1979, The Journal of endocrinology.

[42]  H. Selye,et al.  Shift in adenohypophyseal activity during chronic intermittent immobilization of rats. , 1976, Neuroendocrinology.

[43]  W. Odell,et al.  Physiological control of growth hormone in the rabbit. , 1974, Neuroendocrinology.